Harvard Medical School researchers have found that statin use significantly reduces the risk of hepatocellular carcinoma (HCC ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, accounts for about 75–85% of all liver cancer ...

A research team led by Prof. SUN Cheng from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, along with collaborators from the Agency for Science, ...

AstraZeneca AZN recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi (durvalumab) ...

Namodenoson, has been also granted Orphan Drug Designation by the FDA for pancreatic cancer. The designation as an orphan drug will provide, among others, potential for market exclusivity for seven ...

A research team led by Prof. Sun Cheng from the University of Science and Technology of China (USTC), in collaboration with ...

Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...

This cohort study found that statin use was associated with a reduced risk of hepatocellular carcinoma and hepatic decompensation in ...

Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...

Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone ...